Activation of adenosine A3 receptor alleviates tnf-Induced inflammation through inhibition of the nf- B signaling pathway in human colonic epithelial cells

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Ren, Tianhua ^a   Qiu, Yumei ^a   Wu, Weiyun ^a   Feng, Xiao ^a   Ye, Shicai ^a   Wang, Zhuang ^a   Tian, Ting ^a   He, Yanting ^a   Yu, Caiyuan ^a   Zhou, Yu ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 CHLORO 6 [[(3 IODOPHENYL)METHYL]AMINO] 9H PURIN 9YL] 1 DEOXY N METHYL BETA DEXTRO RIBOFURANURONAMIDE; ADENOSINE A3 RECEPTOR; ADENOSINE A3 RECEPTOR AGONIST; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; MESSENGER RNA; SYNAPTOTAGMIN I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2-CHLORO-N(6)-(3-IODOBENZYL)ADENOSINE-5'-N-METHYLURONAMIDE; ADENOSINE;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; COLON; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOPLASM; ENZYME RELEASE; HT 29 CELL LINE; HUMAN; HUMAN CELL; INFLAMMATION; INTESTINE EPITHELIUM CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; GENETICS; METABOLISM;

ADENOSINE; COLON; EPITHELIAL CELLS; HT29 CELLS; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-8; NF-KAPPA B; RECEPTOR, ADENOSINE A3; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901044618     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/818251     Document Type: Article

References (30)

1. Ye J. H., Rajendran V. M., Adenosine: an immune modulator of inflammatory bowel diseases. World Journal of Gastroenterology 2009 15 36 4491 4498 2-s2.0-71749096599 10.3748/wjg.15.4491
2. Haskó G., Linden J., Cronstein B., Pacher P., Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nature Reviews Drug Discovery 2008 7 9 759 770 2-s2.0-51049101334 10.1038/nrd2638
3. Fredholm B. B., Arslan G., Halldner L., Kull B., Schulte G., Wasserman W., Structure and function of adenosine receptors and their genes. Naunyn-Schmiedeberg's Archives of Pharmacology 2000 362 4-5 364 374 2-s2.0-0033756241 10.1007/s002100000313
4. Gessi S., Merighi S., Varani K., Leung E., Mac Lennan S., Borea P. A., The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacology & Therapeutics 2008 117 1 123 140 2-s2.0-36549081419 10.1016/j.pharmthera. 2007.09.002
5. 3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. Cellular Immunology 2009 258 2 115 122 2-s2.0-67649385777 10.1016/j.cellimm.2009.03.020
6. 3 adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF- B signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. Biochemical Pharmacology 2008 76 4 482 494 2-s2.0-48349143486 10.1016/j.bcp.2008.05.032
7. 3 receptor suppresses lipopolysaccharide-induced TNF-production through inhibition of PI 3-kinase/Akt and NF- B activation in murine BV2 microglial cells. Neuroscience Letters 2006 396 1 1 6 2-s2.0-32544439901 10.1016/j.neulet.2005.11.004
8. 3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. American Journal of Physiology-Regulatory Integrative and Comparative Physiology 2006 291 4 R959 R969 2-s2.0-33749357961 10.1152/ajpregu.00034.2006
9. Maldonado-Contreras A. L., McCormick B. A., Intestinal epithelial cells and their role in innate mucosal immunity. Cell and Tissue Research 2011 343 1 5 12 2-s2.0-79151485800 10.1007/s00441-010-1082-5
10. Turner J. R., Intestinal mucosal barrier function in health and disease. Nature Reviews Immunology 2009 9 11 799 809 2-s2.0-70350509805 10.1038/nri2653
11. Laukoetter M. G., Nava P., Nusrat A., Role of the intestinal barrier in inflammatory bowel disease. World Journal of Gastroenterology 2008 14 3 401 407 2-s2.0-40049097843 10.3748/wjg.14.401
12. Atreya I., Atreya R., Neurath M. F., NF- B in inflammatory bowel disease. Journal of Internal Medicine 2008 263 6 591 596 2-s2.0-43549085501 10.1111/j.1365-2796.2008.01953.x
13. Spehlmann M. E., Eckmann L., Nuclear factor-kappa B in intestinal protection and destruction. Current Opinion in Gastroenterology 2009 25 2 92 99 2-s2.0-64349090821 10.1097/MOG.0b013e328324f857
14. Hayden M. S., Ghosh S., Shared principles in NF- B signaling. Cell 2008 132 3 344 362 2-s2.0-38849199203 10.1016/j.cell.2008.01.020
15. Singh K., Chaturvedi R., Barry D. P., Coburn L. A., Asim M., Lewis N. D., Piazuelo M. B., Washington M. K., Vitek M. P., Wilson K. T., The apolipoprotein E-mimetic peptide COG112 inhibits NF- B signaling, proinflammatory cytokine expression, and disease activity in murine models of colitis. The Journal of Biological Chemistry 2011 286 5 3839 3850 2-s2.0-79952801220 10.1074/jbc.M110.176719
16. Jijon H. B., Walker J., Hoentjen F., Diaz H., Ewaschuk J., Jobin C., Madsen K. L., Adenosine is a negative regulator of NF- B and MAPK signaling in human intestinal epithelial cells. Cellular Immunology 2005 237 2 86 95 2-s2.0-30944436237 10.1016/j.cellimm.2005.10.005
17. Forte G., Sorrentino R., Montinaro A., Pinto A., Morello S., Cl-IB-MECA enhances TNF-release in peritoneal macrophages stimulated with LPS. Cytokine 2011 54 2 161 166 2-s2.0-79953058032 10.1016/j.cyto.2011.02.002
18. -/-AR) on colonic motility or progression of colitis in the mouse. Inflammatory Bowel Diseases 2011 17 8 1698 1713 2-s2.0-79960248344 10.1002/ibd.21553
19. 3 adenosine receptor agonist thio-Cl-IB-MECA through inhibition of Akt and NF- B signaling. Immunobiology 2011 216 9 997 1003 2-s2.0-79960848582 10.1016/j.imbio.2011.03.008
20. 3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis. European Journal of Pharmacology 2003 466 3 323 329 2-s2.0-0037453358 10.1016/S0014-2999(03)01570-X
21. Guzman J., Yu J. G., Suntres Z., Bozarov A., Cooke H., Javed N., Auer H., Palatini J., Hassanain H. H., Cardounel A. J., Javed A., Grants I., Wunderlich J. E., Christofi F. L., ADOA3R as a therapeutic target in experimental colitis: proof by validated high-density oligonucleotide microarray analysis. Inflammatory Bowel Diseases 2006 12 8 766 789 2-s2.0-33747436925 10.1097/00054725-200608000-00014
22. 3 receptors. Journal of Pharmacology and Experimental Therapeutics 2010 335 2 434 442 2-s2.0-78149233636 10.1124/jpet.110.171223
23. Pasparakis M., IKK/NF- B signaling in intestinal epithelial cells controls immune homeostasis in the gut. Mucosal Immunology 2008 1 supplement 1 S54 S57 2-s2.0-54349107492 10.1038/mi.2008.53
24. Li Z., Zhang D. K., Yi W. Q., Ouyang Q., Chen Y. Q., Gan H. T., NF-kappaB p65 antisense oligonucleotides may serve as a novel molecular approach for the treatment of patients with ulcerative colitis. Archives of Medical Research 2008 39 8 729 734 2-s2.0-55249086263 10.1016/j.arcmed.2008.08.001
25. Uwe S., Anti-inflammatory interventions of NF- B signaling: potential applications and risks. Biochemical Pharmacology 2008 75 8 1567 1579 2-s2.0-40949144895 10.1016/j.bcp.2007.10.027
26. Elewaut D., DiDonato J. A., Kim J. M., Truong F., Eckmann L., Kagnoff M. F., NF- B is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria. Journal of Immunology 1999 163 3 1457 1466 2-s2.0-0033178735
27. 3 receptor agonist 2-Cl-IB-MECA in conscious rats. European Journal of Pharmacology 1996 308 3 311 314 2-s2.0-0030601243 10.1016/0014-2999(96)00373- 1
28. 3 receptor and CaMKII. Peptides 2008 29 12 2216 2224 2-s2.0-55949128308 10.1016/j.peptides.2008.09.003
29. Sakowicz-Burkiewicz M., Kitowska A., Grden M., Maciejewska I., Szutowicz A., Pawelczyk T., Differential effect of adenosine receptors on growth of human colon cancer HCT 116 and HT-29 cell lines. Archives of Biochemistry and Biophysics 2013 533 1-2 47 54
30. 3 adenosine subtype. Journal of Cellular Physiology 2007 211 3 826 836 2-s2.0-34247642621 10.1002/jcp.20994